The present invention relates to a genetically modified pig as a model for
studying breast cancer, mitochondria related protein folding disorders
and/or epidermolysis bullosa simplex. The modified pig model displays one
or more phenotypes associated with any of said disorders. Disclosed is
also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA 2
gene, and/or a modified ornithine transcarbamylase gene, and/or a
modified Keratin 14 gene and/or a transcriptional or translational
product or part thereof. The invention further relates to methods for
producing the modified pig; and methods for evaluating the effect of a
therapeutical treatment of breast cancer, mitochondria related protein
folding disorders and/or epidermolysis bullosa simplex; methods for
screening the efficacy of a pharmaceutical composition; and a method for
treatment of a human being suffering from breast cancer, mitochondria
related protein folding disorders and/or epidermolysis bullosa simplex
are disclosed.